{"classes":[{"categories":[{"measurements":[{"comment":"Geometric Coefficient of Variation was not calculated for 2 participants.","groupId":"OG000","lowerLimit":"1.9","spread":"NA","upperLimit":"4.0","value":"2.9"},{"groupId":"OG001","lowerLimit":"1.1","spread":"44","upperLimit":"4.0","value":"4.3"},{"groupId":"OG002","lowerLimit":"1.9","spread":"53","upperLimit":"6.0","value":"4.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Alisertib 35 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 14 days followed by a 14-day recovery period in 28-day cycles until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose).","id":"OG000","title":"Alisertib 35 mg PIC QD 14D"},{"description":"Alisertib 45 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 14 days followed by a 14-day recovery period in 28-day cycles until disease progression or unacceptable alisertib-related toxicity to (up 4 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose).","id":"OG001","title":"Alisertib 45 mg PIC QD 14D"},{"description":"Alisertib 65 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 14 days followed by a 14-day recovery period in 28-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose).","id":"OG002","title":"Alisertib 65 mg PIC QD 14D"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK evaluable population included all participants for whom there were sufficient dosing and alisertib concentration time data to permit non-compartmental PK analysis.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose","title":"CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14","type":"PRIMARY","unitOfMeasure":"L/h"}